David Haas

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi Proinflammatory cytokine and human immunodeficiency virus RNA levels during early Mycobacterium avium complex bacteremia in advanced AIDS
    D W Haas
    Department of Medicine, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37212, USA
    J Infect Dis 177:1746-9. 1998
  2. ncbi Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
    David W Haas
    Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Infect Dis 192:1931-42. 2005
  3. ncbi Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir
    David W Haas
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Acquir Immune Defic Syndr 50:290-3. 2009
  4. ncbi Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans
    David W Haas
    USA
    J Infect Dis 199:872-80. 2009
  5. ncbi MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study
    David W Haas
    Division of Infectious Diseases, Vanderbilt University School of Medicine, 345 24th Avenue, North, Suite 105, Nashville, TN 37212, USA
    J Acquir Immune Defic Syndr 34:295-8. 2003
  6. ncbi Two phases of HIV RNA decay in CSF during initial days of multidrug therapy
    D W Haas
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    Neurology 61:1391-6. 2003
  7. ncbi Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
    David W Haas
    Program for Human Genetics, Vanderbilt University School of Medicine, 345 24th Avenue North, Nashville, TN 37203, USA
    AIDS 18:2391-400. 2004
  8. ncbi Sequence heterogeneity and viral dynamics in cerebrospinal fluid and plasma during antiretroviral therapy
    David W Haas
    Department of Medicine, Division of Infectious Diseases, Vanderbilt Medical School, Nashville, Tennessee 37203, USA
    J Neurovirol 10:33-7. 2004
  9. ncbi Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration
    David W Haas
    Microbiology and Immunology, Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Clin Infect Dis 43:783-6. 2006
  10. ncbi Can responses to antiretroviral therapy be improved by therapeutic drug monitoring?
    David W Haas
    Department of Medicine, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Infect Dis 42:1197-9. 2006

Research Grants

  1. VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
    David Haas; Fiscal Year: 2006
  2. CNS Viral Dynamics and Cellular Immunity During AIDS
    David Haas; Fiscal Year: 2009
  3. Pharmacogenomics of HIV Therapy
    David W Haas; Fiscal Year: 2010

Detail Information

Publications58

  1. ncbi Proinflammatory cytokine and human immunodeficiency virus RNA levels during early Mycobacterium avium complex bacteremia in advanced AIDS
    D W Haas
    Department of Medicine, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37212, USA
    J Infect Dis 177:1746-9. 1998
    ..015). Bacteremia was not associated with increased serum HIV-1 RNA levels. Thus, early MAC bacteremia is associated with increases in serum IL-6 levels, while TNF-alpha levels rise over time during advanced AIDS...
  2. ncbi Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
    David W Haas
    Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Infect Dis 192:1931-42. 2005
    ..Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined associations between genetic variants and long-term responses to treatment...
  3. ncbi Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir
    David W Haas
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Acquir Immune Defic Syndr 50:290-3. 2009
    ..Rifampin is the cornerstone of antituberculosis therapy, but induction of hepatic cytochrome P4503A by rifampin markedly lowers HIV protease inhibitor plasma concentrations...
  4. ncbi Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans
    David W Haas
    USA
    J Infect Dis 199:872-80. 2009
    ..We characterized associations between genetic polymorphisms and the pharmacokinetics of single doses of nevirapine and efavirenz...
  5. ncbi MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study
    David W Haas
    Division of Infectious Diseases, Vanderbilt University School of Medicine, 345 24th Avenue, North, Suite 105, Nashville, TN 37212, USA
    J Acquir Immune Defic Syndr 34:295-8. 2003
    ..It is concluded with 95% confidence that phase 1 viral decay differences between exon 26 TT and CC groups are unlikely to exceed 18%...
  6. ncbi Two phases of HIV RNA decay in CSF during initial days of multidrug therapy
    D W Haas
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    Neurology 61:1391-6. 2003
    ..Defining cellular and tissue sources of HIV-1 in CSF is important for understanding disease pathogenesis and optimal therapies for HIV infection in the brain...
  7. ncbi Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
    David W Haas
    Program for Human Genetics, Vanderbilt University School of Medicine, 345 24th Avenue North, Nashville, TN 37203, USA
    AIDS 18:2391-400. 2004
    ..Efavirenz is metabolized by cytochrome P4502B6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4, CYP3A5, and MDR1 were associated with efavirenz central nervous system side effects and pharmacokinetics...
  8. ncbi Sequence heterogeneity and viral dynamics in cerebrospinal fluid and plasma during antiretroviral therapy
    David W Haas
    Department of Medicine, Division of Infectious Diseases, Vanderbilt Medical School, Nashville, Tennessee 37203, USA
    J Neurovirol 10:33-7. 2004
    ....
  9. ncbi Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration
    David W Haas
    Microbiology and Immunology, Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Clin Infect Dis 43:783-6. 2006
    ..Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016)...
  10. ncbi Can responses to antiretroviral therapy be improved by therapeutic drug monitoring?
    David W Haas
    Department of Medicine, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Infect Dis 42:1197-9. 2006
  11. ncbi Human genetic variability and HIV treatment response
    David W Haas
    Vanderbilt AIDS Clinical Trials Center, 345 24th Avenue North, Suite 105, Nashville, TN 37203, USA
    Curr HIV/AIDS Rep 3:53-8. 2006
    ....
  12. ncbi Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial
    David W Haas
    Vanderbilt University School of Medicine, Nashville, Tennessee 37212, USA
    AIDS 17:1339-49. 2003
    ....
  13. ncbi A randomized trial of interferon alpha therapy for HIV type 1 infection
    D W Haas
    Vanderbilt University Medical Center, Nashville, Tennessee 37212, USA
    AIDS Res Hum Retroviruses 16:183-90. 2000
    ..011). Neutropenia, anemia, and drug intolerance were more common in the IFN-alpha group. This study demonstrates that IFN-alpha inhibits HIV-1 replication but attenuates the CD4+ cell response to dual therapy with ZDV and ddC...
  14. ncbi Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine
    D W Haas
    Vanderbilt University School of Medicine, Nashville, Tennessee 37212, USA
    AIDS 14:1973-8. 2000
    ..To compare the efficacy and safety of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine...
  15. ncbi Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma
    D W Haas
    Division of Infectious Diseases, Department of Medicine and Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37212, USA
    AIDS Res Hum Retroviruses 16:1491-502. 2000
    ..This study supports the utility of ultraintensive CSF sampling for studying HIV-1 pathogenesis and therapy in the CNS, and provides strong evidence that HIV-1 RNA in CSF arises, at least in part, from a source other than plasma...
  16. ncbi Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial
    D W Haas
    Division of Infectious Diseases, Vanderbilt University, Nashville, Tennessee 37212, USA
    J Infect Dis 183:392-400. 2001
    ..023). Responses in efavirenz recipients were sustained at 48 weeks. Thus, efavirenz plus indinavir with concomitant NRTIs is effective therapy for NRTI-experienced patients...
  17. ncbi Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma
    David W Haas
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37212, USA
    Antimicrob Agents Chemother 47:2131-7. 2003
    ..Low-dose ritonavir increases cerebrospinal fluid indinavir concentrations substantially more than 800 mg of indinavir given thrice daily without concomitant ritonavir, despite a lower total daily indinavir dose...
  18. ncbi A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128
    David W Haas
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    HIV Clin Trials 4:287-300. 2003
    ..Human DNA banks must allow future analyses while addressing confidentiality, ethical, and regulatory issues...
  19. ncbi Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study
    David W Haas
    Center for Human Genetics Research, Vanderbilt University, Nashville, TN, 37203, USA
    J Infect Dis 194:1098-107. 2006
    ..Immune recovery during antiretroviral therapy is a complex phenotype that is influenced by multiple genetic variants. Future studies should validate these tentative associations and define underlying mechanisms...
  20. ncbi Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study
    Alison A Motsinger
    Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Pharmacogenet Genomics 16:837-45. 2006
    ..We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms...
  21. ncbi A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
    ..Clinical stability has been observed with continued antiretroviral therapy (ART) in the setting of partial virological suppression. The optimal time to switch treatment in patients with low but detectable HIV-1 RNA is not known...
  22. ncbi Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults
    Leigh Anne Redhage
    Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    HIV Clin Trials 10:181-92. 2009
    ..Plasma F2-isoprostanes (F2-IsoP) reflect lipid peroxidation and oxidant stress and have been described in ART-associated toxicities. We explored factors associated with F2-IsoP in HIV-infected adults...
  23. ncbi Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy
    Todd Hulgan
    Department of Medicine, Vanderbilt Medical School, Nashville, TN 37203, USA
    J Acquir Immune Defic Syndr 34:119-26. 2003
    ..Antiretroviral drug class did not independently predict P-gp activity...
  24. ncbi Will pharmacogenomic discoveries improve HIV therapeutics?
    David W Haas
    AIDS Clincal Trials Center, Vanderbilt University, Nashville, TN, USA
    Top HIV Med 13:90-5. 2005
    ..This article summarizes a presentation on HIV therapeutics and pharmacogenomics by David W. Haas, MD, at the International AIDS Society-USA course in Atlanta in March 2005...
  25. ncbi Enhanced PD-1 expression by T cells in cerebrospinal fluid does not reflect functional exhaustion during chronic human immunodeficiency virus type 1 infection
    Shanmugalakshmi Sadagopal
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Virol 84:131-40. 2010
    ..As inhibition of the PD-1/PD-L1 pathway is pursued as a therapeutic option for viral infections, potential effects of such a blockade on development of autoimmune responses in the CNS should be considered...
  26. ncbi HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells
    Kyra Oswald-Richter
    Department of Microbiology and Immunology, Vanderbilt University Medical School, Nashville, Tennessee, USA
    PLoS Biol 2:E198. 2004
    ..Moreover, the ability to reprogram human T-cells into Treg cells in vitro will greatly aid in decoding their mechanism of suppression, their enhanced susceptibility to HIV infection, and the unique markers expressed by this subset...
  27. ncbi Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study
    Todd Hulgan
    Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    J Acquir Immune Defic Syndr 42:450-4. 2006
    ..Mitochondria play a central role in regulating oxidant stress. We explored the relationships between oxidant stress and NRTI-induced peripheral neuropathy...
  28. ncbi Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy
    Asha R Kallianpur
    Department of Medicine, Divisions of General Internal Medicine and Public Health, Nashville, TN, USA
    AIDS 20:1503-13. 2006
    ..Since iron deficiency is associated with some types of PN, and iron is essential for mitochondrial function, we tested the hypothesis that hemochromatosis (HFE) gene mutations influence susceptibility to NRTI-induced PN...
  29. ncbi Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity
    Marylyn D Ritchie
    Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Infect Dis 43:779-82. 2006
    ..Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001)...
  30. ncbi Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors
    Todd Hulgan
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
    Eur J Clin Pharmacol 65:1081-8. 2009
    ..The aim of our study was to characterize the effects of the P-glycoprotein substrate cyclosporin A on T cell P-glycoprotein activity in human immunodeficiency virus-infected participants in the AIDS Clinical Trials Group study A5138...
  31. ncbi European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142
    Todd Hulgan
    Vanderbilt University, Nashville, Tennessee, USA
    AIDS 25:37-47. 2011
    ..Mitochondrial DNA (mtDNA) influences metabolic diseases and perhaps antiretroviral therapy (ART) complications. We explored associations between European mtDNA haplogroups and metabolic changes among A5142 participants...
  32. ncbi Rapidly increasing prevalence of penicillin-resistant Streptococcus pneumoniae in middle Tennessee: a 10-year clinical and molecular analysis
    Yi Wei Tang
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Clin Microbiol 40:395-9. 2002
    ..Penicillin resistance is rapidly increasing among S. pneumoniae isolates in Tennessee. The simultaneous detection of S. pneumoniae and high-level penicillin resistance can be accurately performed with the six-primer PCR assay...
  33. ncbi African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy
    Jeffrey A Canter
    Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 345 24th Ave North, Nashville, TN 37203, USA
    J Infect Dis 201:1703-7. 2010
    ..7 [95% confidence interval, 1.1-12.0]). An African mtDNA subhaplogroup is for the first time implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated toxicity...
  34. ncbi Oxidant stress is increased during treatment of human immunodeficiency virus infection
    Todd Hulgan
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    Clin Infect Dis 37:1711-7. 2003
    ..Oxidant stress associated with therapeutic control of viral replication may have important implications for long-term complications of antiretroviral therapy...
  35. ncbi Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy
    John P Donahue
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville Veterans Affairs Medical Center, TN 37203, USA
    Clin Pharmacol Ther 73:78-86. 2003
    ....
  36. ncbi Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study
    Todd Hulgan
    Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    AIDS 19:1341-9. 2005
    ..The objective of this study was to determine if NRTI-associated peripheral neuropathy is associated with European mitochondrial haplogroups...
  37. ncbi Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study
    Michael S Boger
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Acquir Immune Defic Syndr 52:480-7. 2009
    ..Little is known about its utility in chronic inflammatory conditions such as HIV infection. We assessed relationships between hsCRP and metabolic parameters over time in HIV-infected patients on ART...
  38. ncbi Enhancement of human immunodeficiency virus (HIV)-specific CD8+ T cells in cerebrospinal fluid compared to those in blood among antiretroviral therapy-naive HIV-positive subjects
    Shanmugalakshmi Sadagopal
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, MCN A2200, Nashville, TN 37232
    J Virol 82:10418-28. 2008
    ..This suggests an important role for HIV-specific CD8(+) T cells in control of intrathecal viral replication...
  39. ncbi Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy
    Todd Hulgan
    Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    J Infect Dis 197:858-66. 2008
    ..Mitochondrial haplogroups and hemochromatosis gene (HFE) polymorphisms have been associated with ART-induced neuropathy. We assessed relationships between these variants and lipoatrophy...
  40. ncbi Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection
    Kyra Oswald-Richter
    Department of Microbiology and Immunology, Vanderbilt University Medical School, Nashville, Tennessee, United States of America
    PLoS Pathog 3:e58. 2007
    ..Determining the host factors within TEMRA cells that restrict R5-tropic viruses and endow HIV-1-specific CD4(+) T cells with this ability may result in novel therapeutic strategies against HIV-1 infection...
  41. ncbi CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection
    Alison Motsinger
    Department of Microbiology and Immunology, Vanderbilt University Medical School, Nashville, TN 37232, USA
    J Exp Med 195:869-79. 2002
    ..Taken together, our findings indicate that CD4(+) NKT cells are directly targeted by HIV-1 and may have a potential role during viral transmission and spread in vivo...
  42. ncbi Human genomic association studies: a primer for the infectious diseases specialist
    Alison A Motsinger
    School of Medicine, Department of Molecular Physiology and Biophysics, Center for Human Genetics Research, Vanderbilt University, Nashville, TN 37232, USA
    J Infect Dis 195:1737-44. 2007
    ..Our goal is to provide the infectious diseases specialist with information that will aid in the critical evaluation of publications that include human genomic analyses...
  43. ncbi Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening
    Timothy R Sterling
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    J Infect Dis 204:893-901. 2011
    ..Identifying factors associated with developing tuberculosis after HAART initiation could focus screening efforts...
  44. ncbi Major outbreak of toxic shock-like syndrome caused by Streptococcus mitis
    Hong-Zhou Lu
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Clin Microbiol 41:3051-5. 2003
    ..This TSLS outbreak in southeastern China was caused by a toxigenic clone of S. mitis. An apparently novel toxin may explain the unusual virulence of this organism...
  45. ncbi Effect of HIV-1 infection on human DNA yield from saliva
    Rebecca J Basham
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
    HIV Clin Trials 10:282-5. 2009
    ..Advanced human immunodeficiency virus (HIV)-type 1 infection disrupts tonsillar architecture and depletes tonsillar lymphocytes. We tested whether HIV-1 infection reduces extracted human DNA yield from saliva...
  46. ncbi Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily
    Edward P Acosta
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 51:3104-10. 2007
    ..Although safe and generally well tolerated, 300 mg or 400 mg atazanavir administered every 12 h did not maintain adequate plasma exposure when coadministered with rifampin...
  47. ncbi Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy
    Alfred J Saah
    Merck Research Laboratories, West Point, PA 19486, USA
    J Infect Dis 187:1157-62. 2003
    ..Suppression to <400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus...
  48. ncbi Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group
    John Spritzler
    Harvard School of Public Health, Boston, Massachusetts, USA
    Clin Infect Dis 37:551-8. 2003
    ..Baseline markers of immune activation and naive/memory lymphocyte subsets had limited ability to predict subsequent discordance...
  49. ncbi Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response
    Donna Mildvan
    Beth Israel Medical Center, New York, New York, USA
    J Infect Dis 189:1811-20. 2004
    ..Total lymphocyte count also predicted a subsequent CD4(+) T cell change. These results document the utility of T cell markers in predicting treatment outcome and their potential value for the study and management of HIV-1 infection...
  50. ncbi A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV
    Constance A Benson
    Division of Infectious Disease, University of Colorado Health Sciences Center, Denver, Colorado, USA
    AIDS 18:2269-76. 2004
    ..CONCLUSION: In stably suppressed patients, 200 mg emtricitabine QD was equivalent to 150 mg lamivudine BID. Emtricitabine-containing HAART was associated with a high rate of sustained virologic suppression during 4 years of follow-up...
  51. ncbi Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study
    Heather J Ribaudo
    Statistical Data Analysis Center, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 42:401-7. 2006
    ..Lower plasma efavirenz clearance is associated with a cytochrome P450 2B6 gene (CYP2B6) polymorphism (516G-->T) that is more frequent among African American individuals than among European American individuals...
  52. ncbi Pharmacogenomics and HIV therapeutics
    David W Haas
    J Infect Dis 191:1397-400. 2005
  53. ncbi Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells
    Patrick R Harrington
    Lineberger Cancer Center, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina 27599-7295, USA
    J Virol 79:7959-66. 2005
    ..We propose that short-lived CD4+ T cells trafficking between the CNS and the periphery play an important role in amplifying and maintaining HIV-1 populations in the CNS during the asymptomatic phase of infection...
  54. ncbi Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    C Bradley Hare
    Dept of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 47:421-4. 2008
    ..Mutations remained detectable for at least 48 weeks in some subjects...
  55. ncbi The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults
    Mustafa A Noor
    Clinical Pharmacology Unit, Bristol Myers Squibb, Princeton, New Jersey 08543, USA
    AIDS 18:2137-44. 2004
    ..Atazanavir (ATV) is a new PI with substantially less in vitro effect on glucose transport than observed with other PI, including lopinavir (LPV) or ritonavir (RTV)...
  56. ncbi Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity
    Todd Hulgan
    J Infect Dis 194:1471-4. 2006
  57. ncbi Multidrug-resistant tuberculosis at an HIV testing center in Haiti
    Patrice Joseph
    , Port-au-Prince, Haiti
    AIDS 20:415-8. 2006
    ..Measures may include appropriate ventilation, outdoor seating, ultra-violet lights, and rapid on-site screening for tuberculosis...
  58. ncbi Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)
    Stephen J Gange
    NA-ACCORD Coordinating Center, Baltimore, MD 21287, USA
    Int J Epidemiol 36:294-301. 2007

Research Grants9

  1. VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
    David Haas; Fiscal Year: 2006
    ..The proposed ACTU will not only enroll patients into ACTG clinical trials, but will provide the ACTG the ability to address important questions concerning AIDS treatment and pathogenesis. ..
  2. CNS Viral Dynamics and Cellular Immunity During AIDS
    David Haas; Fiscal Year: 2009
    ..Characterizing these relationships will expand our knowledge regarding key events that lead to AIDS dementia, and may suggest novel approaches to other immunologic or viral-mediated diseases that affect the brain. ..
  3. Pharmacogenomics of HIV Therapy
    David W Haas; Fiscal Year: 2010
    ..Understanding how human genetic differences predict treatment response to HIV medications may help inform public health policy decisions about the safest and most effective use of antiretroviral regimens in the US and worldwide. ..